Golden Hour Pharma
Golden HourPharma
Back to Services

Ready when it matters most

Oncology Medicines

Golden Hour Pharma facilitates specialised access to critical oncology medicines for hospitals, cancer centres, and national health programmes around the world. Our oncology portfolio includes cytotoxic agents, targeted therapies, monoclonal antibodies, and supportive care medicines — all sourced from WHO-GMP certified facilities.

For detailed product specifications, pricing, and partnership opportunities, please submit your enquiry with the product name (INN), strength, and required quantity.

WHO-GMP CertifiedCold-Chain DeliveryBiosimilar Access
Submit a Product Inquiry
Our Portfolio

Oncology Medicine Categories

A comprehensive oncology portfolio covering conventional chemotherapy, targeted therapies, immunotherapy, and supportive care — for all major cancer types.

01

Cytotoxic Chemotherapy

Conventional chemotherapy agents for solid tumours and haematological malignancies, including alkylating agents, antimetabolites, and topoisomerase inhibitors.

Alkylating agents (Cyclophosphamide, Ifosfamide, Cisplatin, Carboplatin, Oxaliplatin)
Antimetabolites (Methotrexate, 5-Fluorouracil, Gemcitabine, Pemetrexed)
Topoisomerase inhibitors (Doxorubicin, Etoposide, Irinotecan, Topotecan)
Taxanes (Paclitaxel, Docetaxel, Cabazitaxel)
Vinca alkaloids (Vincristine, Vinblastine, Vinorelbine)
02

Targeted Therapies & Kinase Inhibitors

Molecularly targeted agents for cancers with specific genetic or protein markers, including tyrosine kinase inhibitors and mTOR pathway inhibitors.

BCR-ABL inhibitors for CML (Imatinib, Dasatinib, Nilotinib)
EGFR inhibitors (Erlotinib, Gefitinib, Afatinib, Osimertinib)
VEGFR inhibitors and anti-angiogenic agents
CDK 4/6 inhibitors for breast cancer
BRAF/MEK inhibitors for melanoma
03

Monoclonal Antibodies & Immunotherapy

Advanced monoclonal antibody formulations and immunotherapy agents targeting tumour-associated antigens and immune checkpoint pathways.

PD-1/PD-L1 checkpoint inhibitors (Pembrolizumab, Nivolumab)
CTLA-4 inhibitors (Ipilimumab)
Anti-CD20 antibodies (Rituximab and biosimilars)
Anti-HER2 agents (Trastuzumab and biosimilars)
Anti-VEGF antibodies (Bevacizumab and biosimilars)
04

Hormone Therapies

Hormonal and endocrine therapies for hormone-sensitive cancers including breast cancer and prostate cancer.

Aromatase inhibitors (Anastrozole, Letrozole, Exemestane)
Anti-oestrogens (Tamoxifen, Fulvestrant)
LHRH analogues (Leuprolide, Goserelin, Buserelin)
Anti-androgens (Bicalutamide, Enzalutamide, Abiraterone)
05

Supportive Oncology Medicines

Essential supportive care medicines to manage chemotherapy side effects and maintain patient quality of life through treatment.

Anti-emetics (Ondansetron, Granisetron, Aprepitant)
G-CSF / Colony stimulating factors (Filgrastim, Pegfilgrastim)
Erythropoiesis stimulating agents
Bone modifying agents (Zoledronic acid, Denosumab)
Mucositis management and supportive care
06

Haematology & Iron Chelation

Specialist medicines for haematological malignancies and associated conditions including thalassemia requiring long-term management.

Hypomethylating agents (Azacitidine, Decitabine) for MDS/AML
Proteasome inhibitors (Bortezomib, Carfilzomib) for myeloma
Iron chelation therapy (Deferasirox, Deferiprone, Deferoxamine)
Thrombopoietin receptor agonists
Supportive transfusion and haematopoietic medicines
Our Capabilities

Reliable Oncology Supply for Hospitals & Cancer Centres

We support hospitals, cancer treatment centres, and national health programmes across MENA, Africa, Latin America, and global markets with consistent, compliant, and cost-effective access to critical oncology medicines. Cold-chain assured delivery and full regulatory documentation are standard.

Cytotoxic chemotherapy agents for solid and haematological cancers
Targeted therapies and kinase inhibitors
Monoclonal antibodies — originator and biosimilar formulations
Hormone therapies and immunotherapies
Supportive oncology medicines (antiemetics, G-CSF, bone agents)
Cold-chain assured delivery to hospitals and cancer centres worldwide
WHO-GMP certified manufacturing for all products
Full regulatory documentation for all export markets
Contract manufacturing capabilities for specialist formulations

Submit a Product Inquiry

For specific product availability, pricing, cold-chain requirements, and regulatory documentation — submit your inquiry with the details below.

1
Product name (INN / generic name)
2
Strength and dosage form
3
Brand reference (originator or biosimilar)
4
Destination country
5
Required quantity and frequency
Submit an Inquiry